The anticancer activity of malvidin was studied in Dalton's lymphoma ascites (DLA)-induced solid and ascitic tumor mice models. Malvidin is a natural compound belonging to the family of O-methylated anthocyanidin and plays a predominant role in regulating both short- and long-term cellular activities. Animals were injected with DLA cells (1.5 × 10⁶ cells/animal) to induce solid and ascitic tumors. The administration of malvidin (5 mg/kg bw and 10 mg/kg bw) was carried out for 10 consecutive days from the day of tumor induction for both solid and ascitic tumors. Cyclophosphamide, CTX (25 mg/kg bw), used as the standard drug, was also administered for 10 consecutive days. Treatment with malvidin showed a significant reduction in tumor volume and elevated white blood cell (WBC) count when compared to the DLA-bearing control animals. The treatment also maintained the body weight and hemoglobin level, and decreases in aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT) were also noted. This investigation also reported the decreased levels of cellular glutathione (GSH) in ascitic tumor groups. Malvidin reduced inflammatory mediator and cytokine levels, such as tumor necrosis factor level alpha (TNF-α) and interleukin-6 (IL-6), which serve as molecular targets for cancer prevention. A decrease in the level of reactive oxygen species (ROS), like nitric oxide (NO), was observed. Histopathological examination revealed altered morphological changes in tumor tissue and the alleviation of hepatic architecture due to DLA. Immunohistochemical analysis revealed the inhibition of iNOS. This study demonstrated that malvidin exhibited significant in vivo antitumor activity and that it was reasonably imputable to its increasing endogenous mechanism. We accent the pertinence of malvidin as a potential naturally derived drug target for tumor control.

中文翻译：

---

malvidin消除氧化应激和炎症介质，以抑制小鼠实体和腹水肿瘤的发展。

在道尔顿淋巴瘤腹水（DLA）诱导的实体和腹水肿瘤小鼠模型中研究了malvidin的抗癌活性。Malvidin是属于O-甲基化花青素家族的天然化合物，在调节短期和长期细胞活性中起主要作用。给动物注射DLA细胞（1.5×10 ⁶细胞/动物）诱导实体瘤和腹水瘤。对于实体瘤和腹水瘤，从肿瘤诱导之日起连续10天服用麦维达汀（5 mg / kg bw和10 mg / kg bw）。环磷酰胺CTX（25 mg / kg bw），用作标准药物，也连续服用10天。与带有DLA的对照动物相比，用麦维达汀治疗可显着减少肿瘤体积并增加白细胞（WBC）数量。该治疗还保持了体重和血红蛋白水平，并且还注意到天冬氨酸转氨酶（AST），丙氨酸转氨酶（ALT），碱性磷酸酶（ALP），γ-谷氨酰转移酶（GGT）降低。这项研究还报告了腹水肿瘤组中细胞谷胱甘肽（GSH）的水平降低。Malvidin降低了炎症介质和细胞因子的水平，例如肿瘤坏死因子水平α（TNF-α）和白介素6（IL-6），它们是预防癌症的分子靶标。观察到一氧化氮（NO）等活性氧（ROS）含量下降。组织病理学检查显示，由于DLA，肿瘤组织的形态变化发生改变，肝脏结构减轻。免疫组织化学分析显示iNOS的抑制作用。这项研究表明，malvidin表现出明显的 组织病理学检查显示，由于DLA，肿瘤组织的形态变化发生改变，肝脏结构减轻。免疫组织化学分析显示iNOS的抑制作用。这项研究表明，malvidin表现出明显的 组织病理学检查显示，由于DLA，肿瘤组织的形态变化发生改变，肝脏结构减轻。免疫组织化学分析显示iNOS的抑制作用。这项研究表明，malvidin表现出明显的体内抗肿瘤活性，并且可以合理地归因于其增加的内源性机制。我们强调了malvidin作为一种潜在的天然来源的肿瘤控制药物靶点的相关性。